Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novan Inc (NQ: NOVN )

0.8526 -0.0618 (-6.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 338,103
Open 0.8900
Bid (Size) 0.8522 (1)
Ask (Size) 0.9000 (10)
Prev. Close 0.9144
Today's Range 0.8500 - 0.9300
52wk Range 0.7900 - 3.330
Shares Outstanding 18,813,192
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
From Novan, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga

Performance

YTD
-48.64%
-48.64%
1 Month
-25.21%
-25.21%
3 Month
-36.84%
-36.84%
6 Month
-30.11%
-30.11%
1 Year
-69.98%
-69.98%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Novan Focuses Strategic Direction and Announces Restructuring
From Novan, Inc.
Via GlobeNewswire
Earnings Preview: Novan
Via Benzinga
Novan's Return On Capital Employed Overview
Via Benzinga
Earnings Outlook For Novan
Via Benzinga
Looking Into Novan's Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Via Benzinga
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Novan, Inc.
Via GlobeNewswire
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
From Novan, Inc.
Via GlobeNewswire
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
From Novan, Inc.
Via GlobeNewswire
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
From Novan, Inc.
Via GlobeNewswire
Earnings Scheduled For March 30, 2023
Via Benzinga
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
From Novan, Inc.
Via GlobeNewswire
Novan to Report Full Year 2022 Financial Results on March 30, 2023
From Novan, Inc.
Via GlobeNewswire
Novan Announces Closing of $6.0 Million Registered Direct Offering
From Novan, Inc.
Via GlobeNewswire
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Novan, Inc.
Via GlobeNewswire
Novan Announces $6.0 Million Registered Direct Offering
From Novan, Inc.
Via GlobeNewswire
Novan Moves Forward with Unified Corporate Branding
From Novan, Inc.
Via GlobeNewswire
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
From Novan, Inc.
Via GlobeNewswire
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
From Novan, Inc.
Via GlobeNewswire
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Novan, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.